RLMD
RELMADA THERAPEUTICS, INC.BS score 50.0MEDIUMPHASE3 · mkt cap $798.2M · rev ttm $0
drug hypothesis
REL-1017 modulates Not specified in provided data to treat Major Depressive Disorder.
moa:Not specified in provided data - appears to be an NMDA receptor antagonist based on company filings (esmethadone/prodrug)
score breakdown
trial design70
base rate disconnect15
language red flags80
composite50.0
valuation analysis
market cap$798.2M
revenue ttm$0
phasePHASE3
historical base rate30%
disconnect ratio0.5x
lead trialNCT07313891
meta
cik0001553643
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 3, single-arm, non-randomized, non-placebo-controlled safety study enrolling 627 patients with Major Depressive Disorder. Primary focus on monitoring treatment-emergent adverse events, QTc interval changes, blood pressure, heart rate, and weight over 52 weeks.
primary endpoint:Safety and Tolerability of REL-1017 as Incidence of Treatment Emergent Adverse Events (TEAEs) over 52 weeks
claimed differentiation
Not specified in provided data
language red flags
- Phase 3 study with non-randomized, non-placebo-controlled design is atypical for regulatory approval pathway
- Primary endpoint is safety/tolerability only, not efficacy - suggests limited efficacy data at time of trial design
- Lack of randomization and placebo control limits interpretability of any effectiveness signals
- Trial completed 2021-2023 but limited efficacy data available in this dataset